Table 1. Patient characteristics.
| Entire cohort (n=56) | Cardiotoxicity (n=10) | No-cardiotoxicity (n=46) | |
|---|---|---|---|
| Age, y | 49.9±3.3 | 48.6±3.2 | 49.9±1.2 |
| Hypertension | 5 (8.5) | 1 (10) | 5 (10.9) |
| Diabetes mellitus | 1 (1.7) | 0 (0) | 1 (2.2) |
| Current or past smokers | 17 (28.8) | 5 (50) | 13 (28.3) |
| Body mass index, kg/m2 | 28.5±3.3 | 27.5±6.5 | 29.4±1.1 |
| Doxorubicin total dose, mg/m2 | 410.3±9.5 | 408.4±1.4 | 410.6±11.4 |
| Menopause | |||
| Pre | 29 (49.2) | 5 (50) | 22 (47.8) |
| Post | 30 (50.8) | 5 (50) | 24 (52.2) |
| Breast cancer side | |||
| Right | 28 (47.5) | 4 (40) | 21 (45.7) |
| Left | 30 (50.8) | 6 (60) | 24 (52.2) |
| Bilateral | 1 (1.7) | 0 (0) | 1 (2.2) |
| Baseline LVEF, % | 65.3±0.5 | 67.2±1.0 | 64.9±0.5 |
Values are expressed as mean±SEM or n (%); LVEF - Left ventricle ejection fraction.